A protease can be defined as an enzyme that hydrolyses peptide bonds. Proteases can be divided into endopeptidases, which cleave internal peptide bonds in substrates, and exopeptidases, which cleave the terminal peptide bonds. Exopeptidases can be further subdivided into aminopeptidases and carboxypeptidases. The Schechter and Berger nomenclature provides a model for describing the interactions between the peptide substrate and the active site of a protease. Proteases can also be classified as aspartic proteases, cysteine proteases, metalloproteases, serine proteases and threonine proteases, depending on the nature of the active site. Different inhibitors can be used experimentally to distinguish between these classes of protease. The MEROPs database groups proteases into families on the basis of similarities in sequence and structure. Protease activity can be regulated in vivo by endogenous inhibitors, by the activation of zymogens and by altering the rate of their synthesis and degradation.
Introduction
For many researchers, proteases are often considered to be unwanted biological pests. Many do their utmost to inactivate proteases in order to prevent the breakdown of their particular protein of interest. For others, proteases are tools to be used to selectively destroy or chop up a protein prior to its further analysis, e.g. the digestion of a protein with trypsin prior to sequencing the smaller tryptic fragments. However, more and more researchers are recognizing that proteases are often key players in a wide range of biological processes; for example, in regulating the cell cycle, cell growth and differentiation, antigen processing and angiogenesis. In addition, it is becoming apparent that the aberrant functioning of certain proteases may be involved in several disease states, including Alzheimer's disease, in cancer metastasis and in inflammation. An understanding of the role played by proteases in these processes may provide the opportunity for therapeutic intervention, and inhibitors of certain proteases have already proved to be effective therapeutic agents in hypertension and heart failure, some forms of cancer, and against certain viruses. The aim of this volume is to highlight some of the more recent developments in this area and to provide an insight into the future of protease research. When one considers that almost 2% of the human genome codes for proteases [1] , it is clear that there is a lot still to be learned. The remainder of this chapter is devoted to a brief introduction to the basic terminology used in protease biology.
Definition of proteases
A protease is defined as an enzyme that hydrolyses one or more peptide bonds ( Figure 1 ) in a protein or peptide [2] . Thus, proteases can, potentially, degrade anything containing a peptide bond, from a dipeptide up to a large protein containing thousands of amino acids. However, many proteases have a preference for protein substrates, while others will only cleave short peptides or even just dipeptides. As these enzymes hydrolyse peptide bonds, some have argued that they all should be termed 'peptidases', and that the term 'protease' be restricted to those peptidases that hydrolyse proteins. Other commonly found terms in the literature include 'proteinase' and 'proteolytic enzyme'.
Cleavage-site specificity
The terminology used in describing the cleavage-site specificity of proteases is based on a model proposed by Schechter and Berger [3] . In this model, the catalytic site is considered to be flanked on one or both sides by specificity subsites, each of which is able to accommodate the side chain of a single amino acid residue (Figure 2 ). By convention, the substrate amino-acid residues are called P (for peptide) and the subsites on the protease that interact with the substrate are called S (for subsite). The subsites are numbered outwards from the catalytic site, S1, S2, S3, etc. towards the N-terminus of the substrate, and S1Ј, S2Ј, S3Ј, etc. towards the C-terminus (Figure 2 ). The side chains of the amino-acid residues in the substrate that these sites accommodate are numbered P1, P2, etc. and P1Ј, P2Ј, etc., outwards from the scissile peptide bond (see Figure 2) . The residues are usually not numbered beyond P6 on either side of the scissile bond. Different proteases have different requirements for subsite interactions to determine the specificity of cleavage. For example, the S1 subsite of trypsin has a marked preference for the binding of basic amino acid residues (arginine and lysine), while interactions with several of the subsites further away from the scissile bond are critical for substrate binding to renin, the protease involved in the renin-angiotensin system (see Chapter 10), and to the caspases, proteases involved in apoptosis (see Chapter 2).
Classification of proteases
Why classify proteases? First, classification aids researchers and students in understanding the terminology in this large, and often confusing, field of research. Secondly, the grouping together of enzymes in families on the basis of sequence and structural information aids in the elucidation of common catalytic, biosynthetic processing and regulatory mechanisms. Finally, such classification is invaluable in elucidating the function of newly identified proteases. This is particularly relevant in the context of proteases that are 
Figure 2. The Schechter and Berger [3] nomenclature for binding of a peptide substrate to a protease
The protease is represented as the blue shaded area. P1, P1Ј, etc. are the side chains of the six amino acids surrounding the peptide bond to be cleaved (indicated by the arrow) in the substrate. S1, S1Ј, etc. are the corresponding subsites on the protease.
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initially identified on the basis of sequence similarity from screening genome databases [1] , rather than in the more traditional way of isolating an activity that cleaves a particular protein or peptide substrate, followed by its purification and experimental characterization. Mining of genome databases for novel proteases is dealt with in more detail in Chapter 14. Proteases can be classified on the basis of the position within a peptide of the peptide bond that is cleaved. Thus, endopeptidases cleave internal peptide bonds, while exopeptidases cleave the terminal bonds (Figure 3) . Exopeptidases can be further subdivided into aminopeptidases or carboxypeptidases, depending on whether they cleave the N-terminal or C-terminal peptide bond respectively (Figure 3) . Proteases are also classified on the basis of the catalytic mechanism, that is, the nature of the amino acid residue or cofactor at the active site that is involved in the hydrolytic reaction. Thus, aspartic proteases, such as the HIV protease (see Chapter 9) and renin (see Chapter 10), have a critical aspartate residue that is involved in catalysis. Metalloproteases have a bivalent metal ion, usually zinc but sometimes cobalt, iron or manganese, at the active site. Examples of metalloproteases include the matrix metalloproteases (see Chapter 3), methionine aminopeptidases (see Chapter 6), angiotensin-converting enzyme and neprilysin (see Chapter 10), and the ADAMs (a disintegrin and metalloproteinase domain) family of proteases (see Chapter 11). In the aspartic and metalloproteases, the nucleophile that attacks the peptide bond of the substrate is an activated water molecule, whereas in the other protease groups the nucleophile is part of an amino acid at the catalytic site of the protease.
Those proteases in which the nucleophile is the sulphydryl group of a cysteine residue are termed cysteine proteases, typified by the caspases that are involved in programmed cell death (see Chapter 2). In serine proteases the catalytic mechanism depends upon the hydroxy group of a serine residue acting as the nucleophile that attacks the peptide bond. Examples of serine proteases include chymotrypsin and trypsin (digestive enzymes of the intestine), and the proteases involved in the blood clotting cascade (see Chapter 8) . In a small number of proteases the catalytic mechanism depends on the hydroxy group of a threonine residue, the so-called threonine proteases. These are exemplified by . At present, 3% of the proteases in the human genome have been identified as aspartic proteases, 23% as cysteine proteases, 36% as metalloproteases and 32% as serine proteases [1] . Over the past decade, Alan Barrett and his colleagues in Cambridge, U.K., have developed a more detailed classification system for proteases, the MEROPS database [4] [5] [6] . This is available online (www.merops.ac.uk) or in hard copy as the Handbook of Proteolytic Enzymes [7] . In the MEROPS database, proteases are classified by structural similarities in the parts of the molecules that are responsible for their enzymic activity. They are grouped into families on the basis of amino-acid sequence homology, and the families are assembled into clans based on evidence, usually similarities in tertiary structure, that they share a common ancestry (Figure 4) . This classification forms a framework around which a wealth of supplementary information about the proteases is organized, including images of three-dimensional structures, amino-acid sequence alignments, comments on biomedical relevance, and literature references. A set of online searches provides access to information about the location of proteases on human chromosomes and their substrate specificity. As the MEROPS database is updated regularly, it provides an extremely valuable resource for protease researchers (see also Chapter 14).
Inhibition of proteases
The four major classes of proteases (aspartic, cysteine, metallo and serine) can be distinguished experimentally using class-specific inhibitors (Table 1) . For example, chelators such as EDTA or 1,10-phenanthroline remove the critical metal ion from the catalytic site of metalloproteases, thereby inactivating them. On the other hand, di-isopropyl fluorophosphate binds irreversibly to the serine residue at the catalytic site of serine proteases, thus permanently inactivating the enzyme. However, not every protease is susceptible to inhibition by one of these more general class-specific inhibitors. For example, the recently discovered aspartic protease involved in the ␤-secretase cleavage of the Alzheimer's disease amyloid precursor protein is not inhibited by pepstatin [8] (see Chapter 4). These class-specific inhibitors (Table 1) can be used experimentally to identify the catalytic type that a particular protease belongs to, and are particularly useful in the absence of amino-acid sequence information. In addition, knowledge of the different protease classes and their respective inhibitors is often useful in designing a strategy to block the breakdown of a particular protein in a sample by the inhibition of either as many proteases as possible or a discrete subgroup of proteases. To this end, inhibitor cocktails, consisting of mixtures of the compounds in Table 1 , are available from a number of commercial suppliers.
Regulation of protease activity
In addition to the inhibition of proteases in vitro, there are several ways in which the activities of proteases can be regulated in vivo. These include inhibition by endogenous inhibitors, which are often proteins themselves, such as the antitrypsin inhibitor that binds to prematurely activated trypsin in the pancreas, the serine protease inhibitors and Kunitz-type protease inhibitors that inhibit, amongst others, some of the serine proteases involved in blood clotting (see Chapter 8), the tissue inhibitors of metalloproteases that inhibit the matrix metalloproteases (see Chapter 3), and the inhibitor of apoptosis proteins that inhibits the caspases (see Chapter 2) .
Protease activity can also be regulated in other ways. The rate of synthesis and/or the rate of degradation will determine the amount of a particular protease present at any one time. Such mechanisms are often used to restrict the expression and activity of a protease to a particular tissue or stage of development. Many proteases are first synthesized in an inactive pro-form, often termed a zymogen, which is itself proteolytically cleaved to the active protease, e.g. trypsinogen is activated to form the digestive enzyme trypsin. Other examples include the matrix metalloproteases (see Chapter 3), the ADAMs family (see Chapter 11) and the serine proteases involved in blood clotting (see Chapter 8) . The latter case is an excellent example of a series of zymogen activations finely regulating a biological process. Several zymogens are activated by the removal of their prodomain by serine proteases of the furin/pro-hormone convertase family that cleave at pairs of dibasic residues (see Chapter 7). The mode of inhibition is indicated as either reversible (R) or irreversible (I). More information on individual inhibitors can be found in [9] or the supplier's catalogues. 
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